Rendering courtesy of The RMR Group Unison LifeScience
Sonoma Bio to cement its roots in Seattle with a new waterfront manufacturing and R&D site
A year after Jeff Bluestone’s Sonoma Biotherapeutics netted $265 million in a huge Series B, the biotech is now looking to establish itself in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
